Baricitinib
- Generic Name
- Baricitinib
- Brand Names
- Olumiant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N7O2S
- CAS Number
- 1187594-09-7
- Unique Ingredient Identifier
- ISP4442I3Y
- Background
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...
- Indication
In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...
- Associated Conditions
- Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2600
- Registration Number
- NCT03915964
- Locations
- 🇺🇸
Medvin Clinical Research - Covina, Covina, California, United States
🇺🇸Robin K. Dore MD, Inc, Tustin, California, United States
🇺🇸Medvin Clinical Research - Whittier, Whittier, California, United States
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 546
- Registration Number
- NCT03899259
- Locations
- 🇦🇷
Centro de Investigaciones Médicas Tucuman, SAN M. DE Tucuman, Tucuman, Argentina
🇧🇷Hospital de Clínicas Da Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil
🇧🇷Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1147
- Registration Number
- NCT03843125
- Locations
- 🇺🇸
New England Research Associates, Bridgeport, Connecticut, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸Integral Rheumatology & Immunology Specialists, Plantation, Florida, United States
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 220
- Registration Number
- NCT03773978
- Locations
- 🇨🇳
Children's Hospital of Soochow University, Suzhou, China
🇦🇺Royal Childrens Hospital Melbourne, Parkville, Victoria, Australia
🇦🇷Centro Medico Privado de Reumatologia, SAN M. DE Tucuman, Tucumán, Argentina
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 190
- Registration Number
- NCT03773965
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇨🇳Beijing Peking Union Medical College Hospital, Beijing, Beijing, China
🇯🇵Institute of Science Tokyo Hospital, Bunkyō, Tokyo, Japan
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2
- Registration Number
- NCT03742973
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸UH Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 329
- Registration Number
- NCT03733301
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇯🇵Kawashima Dermatology Clinic, Ichikawa-shi, Chiba, Japan
🇯🇵Yamano Dermatological Clinic, Dazaifu, Fukuoka, Japan
Effect of Baricitinib Treatment on Peripheral Bone in RA
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 15
- Registration Number
- NCT03701789
- Locations
- 🇩🇪
Universitiy Hospital Erlangen, Erlangen, Bavaria, Germany
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 778
- Registration Number
- NCT03616964
- Locations
- 🇵🇱
Centrum Medyczne AMED, Warszawa, Poland
🇺🇸Joint and Muscle Medical Care, Charlotte, North Carolina, United States
🇺🇸Arthritis and Osteoporosis Associates of New Mexico, Las Cruces, New Mexico, United States
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 830
- Registration Number
- NCT03616912
- Locations
- 🇧🇪
CHU de Liège, Liège, Belgium
🇬🇷University General Hospital of Larissa, Larissa, Greece
🇭🇷Clinical Hospital Dubrava, Zagreb, Croatia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.